Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received a consensus rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $77.67.

ANAB has been the subject of a number of recent analyst reports. JMP Securities lifted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research report on Tuesday, October 10th. Credit Suisse Group raised their price objective on shares of AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Robert W. Baird began coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an “outperform” rating and a $36.00 price objective for the company. Finally, Royal Bank Of Canada began coverage on shares of AnaptysBio in a research note on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price objective for the company.

WARNING: “AnaptysBio, Inc. (ANAB) Receives Consensus Recommendation of “Buy” from Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/18/anaptysbio-inc-anab-receives-consensus-recommendation-of-buy-from-analysts.html.

In other news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Holdings A/S Novo sold 70,706 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the sale, the insider now owns 3,009,949 shares of the company’s stock, valued at approximately $70,161,911.19. The disclosure for this sale can be found here. Insiders have sold a total of 1,133,940 shares of company stock valued at $24,223,316 in the last 90 days.

Several large investors have recently modified their holdings of ANAB. Artal Group S.A. lifted its position in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $3,851,000. Geode Capital Management LLC purchased a new stake in shares of AnaptysBio during the 1st quarter worth approximately $1,522,000. Northern Trust Corp lifted its position in shares of AnaptysBio by 360.6% during the 2nd quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock worth $1,436,000 after buying an additional 47,005 shares during the last quarter. Finally, Spark Investment Management LLC lifted its position in shares of AnaptysBio by 113.5% during the 2nd quarter. Spark Investment Management LLC now owns 74,100 shares of the biotechnology company’s stock worth $1,773,000 after buying an additional 39,400 shares during the last quarter. Institutional investors and hedge funds own 71.35% of the company’s stock.

Shares of AnaptysBio (NASDAQ:ANAB) opened at 65.52 on Wednesday. AnaptysBio has a 12 month low of $15.17 and a 12 month high of $74.00. The stock has a 50 day moving average of $36.95 and a 200 day moving average of $27.78. The stock’s market cap is $1.33 billion.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $3.45 million. On average, equities analysts anticipate that AnaptysBio will post ($1.99) earnings per share for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.